Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.

被引：0
|
作者：
Schmitt, C
Levy-Piedbois, C
Frappé, M
Durand-Zaleski, I
Gruia, G
Alakl, M
Rougier, P
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Aventis Pharma, Antony, France
[3] Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France
[4] Inst Gustave Roussy, Dept Publ Hlth & Informat, Villejuif, France
[5] Phoenix Int, MDS Pharma Serv, Sevres, France
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [42] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Michalaki, V.
    Gennatas, C.
    Gennatas, S.
    Vasiliou, J.
    Smyrniotis, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Park, SH
    Bang, SM
    Cho, EK
    Baek, JH
    Oh, JH
    Im, SA
    Park, YS
    Shin, DB
    Lee, JH
    ONCOLOGY, 2004, 66 (05) : 353 - 357
  • [44] Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer - Reply
    Fuchs, Charles S.
    Marshall, John
    Barrueco, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1908 - 1909
  • [45] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Papalambros, E.
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1923 - 1926
  • [46] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Michalaki, V.
    ANNALS OF ONCOLOGY, 2008, 19 : I45 - I45
  • [47] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [48] Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer.
    Tan, Chia Jie
    Liu, Haopeng
    Farrokhi, Pegah
    Garrido-Laguna, Ignacio
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [49] A phase II study of irinotecan, fluoroxuridine and leucovorin (IFLUX) as a first-line chemotherapy in advanced colorectal cancer.
    Ardalan, B
    Livingstone, A
    Franceschi, D
    Santos, E
    Lima, M
    Kozyreva, O
    Tsai, KT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 270S - 270S
  • [50] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
12345